All In Biotech

Drug Trial Radar · NCT06221241

Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

A Phase 2, Multicenter, Randomized, Double-blind, Placebo and Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

Last checked: Nov 20, 2026Latest source record: Apr 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

220

Planned (sponsor's estimate)

Start

Mar 25, 2024

Primary completion

Mar 14, 2025

Study completion Apr 30, 2025

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Multicenter, Randomized, Double-blind, Placebo and Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX000623 in Participants with Diabetic Peripheral Neuropathic Pain

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

  • JMKX000623Drug

    tablets for oral administration.

  • PregabalinDrug

    capsules for oral administration.

  • PlaceboDrug

    matched to JMKX000623 and Pregabalin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of the Average Daily Pain Score (ADPS) from baseline to Week 12. [ADPS is the weekly average pain score based on the 11-point numeric rating scale (NRS)]Time frame: baseline,Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.